SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joe Copia who wrote (3676)5/28/1998 4:53:00 PM
From: musicguy  Read Replies (2) of 25711
 
Joe, THIS paragraph seems to be the important one (as far as I am concerned)

"The Company is currently conducting in-house clinical studies monitored by an Institutional Review Board (IRB) of approximately fifteen to twenty patients whose studies will establish image interpretation criteria for PMA submission. Upon completion of the first phase clinical studies, the Company will commence the second
phase clinical trials at three prominent hospitals."

here's where it gets exciting..

"The Company will launch manufacturing of its CT Laser Mammography (CTLM(TM)) Systems immediately following the first phase clinical trials to ensure timely delivery of systems to the Company's European customers."

How long do we imagine the phase 1 in house trials will take? Does anyone here have any clinical experience with this sort of thing?

If the results are as good as we all hope, manufacturing begins soon. By year end, could we be looking at units actually shipping to US hospitals? Could we see units in use in Europe before then? The only question in my tiny mind is about the time frame, but I don t mind waiting for this one....

I like this one a lot,

If I could have only 2 stocks, they would be NUKE and IMDS.

Thanks for both...

MG
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext